Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2511 in Early Alzheimer's Disease
NCT07768592Phase 1Not yet recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2026
- Primary completion
- May 2030
01
Overview
Phase 1, randomised, open-label trial of E2511 in Alzheimer's disease (AD) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Change from Baseline in [11C]MK-6884 Positron Emission Tomography Using Non-Displaceable Binding Potential at 14 days, Number of Participants With Adverse Events at 91 weeks and 6 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
E2511
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07768592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768592.